Vivimed Labs Ltd's Q2FY17 standalone net profit rises 12.44% yoy to Rs.26.85 crore : Misses Estimates

India Infoline Research Team | November 15, 2016 16:04 IST

Vivimed Labs Ltd Q2FY17

Standalone Results Q2FY17: (Rs. in crore)

Q2FY17 YoY (%)
Revenue 299.29 [12.4]
EBITDA 61.22 [3.1]
EBITDA Margin (%) 20.5 196
Net Profit (adjusted) 26.85 12.4
***EBITDA margin change is bps

Vivimed Labs  Ltd’s Q2FY17 standalone numbers missed Bloomberg estimates. Revenue for the period came in 21.2% below estimate of Rs 380 cr. Also, reported net profit for the period came in 5.8% below the estimate of Rs 29 cr.
Revenue for the quarter declined by 12.4% yoy to Rs 299.29 cr. Speciality chemical segment registered 24% yoy de-growth to Rs 45 cr.

EBITDA declined by 3.1% yoy to Rs 61.22 cr while EBITDA margins expanded 196 bps yoy to 20.5%. Employee cost has increased 10% yoy to Rs 41.41 cr.

Net profit increased by 12.44% yoy to Rs 26.85 cr. This was driven by dip in finance cost of  21% yoy to Rs 14.94 cr..

Technical View:

Vivimed Labs Ltd is currently trading at Rs. 87.8, down by 5.95 points or 6.35% from its previous closing of Rs. 93.75 on the BSE.
The scrip opened at Rs. 93.7 and has touched a high and low of Rs. 93.7 and Rs. 85.25 respectively. So far 374298(NSE+BSE) shares were traded on the counter. The stock is currently trading above its 50 DMA.

BSE 92.60 0.40 (0.43%)
NSE 92.90 0.70 (0.76%)

***Note: This is a NSE Chart

 

Advertisements

  • Get your free IIFL Demat & Trading A/c now...Click here
  • Get IIFL express personal loan disbursal in just 8* hours...Know More
  • Get the most detailed result analysis on the web - Real Fast!
  • Actionable & Award-Winning Research on 500 Listed Indian Companies.